Report - CE-1 Exjade ® (deferasirox; ICL670) Efficacy and Safety Peter Marks, MD, PhD Senior Director, Clinical Development Novartis Pharmaceuticals Corporation.

Select PornographicDefamatoryIllegal/UnlawfulSpamOther Terms Of Service ViolationFile a copyright complaint

Please pass captcha verification before submit form